Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond

Eitemau Tebyg

• Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
  gan: Suda, Kenichi, et al.
  Cyhoeddwyd: (2021)
• Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges
  gan: Fujino, Toshio, et al.
  Cyhoeddwyd: (2021)
• Molecular epidemiology of lung cancer and geographic variations with special reference to EGFR mutations
  gan: Mitsudomi, Tetsuya
  Cyhoeddwyd: (2014)
• Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation
  gan: Suda, Kenichi, et al.
  Cyhoeddwyd: (2016)
• The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations
  gan: Okamoto, Isamu, et al.
  Cyhoeddwyd: (2010)